Michal Shahar

Michal Shahar, PhD, currently serves as VP R&D at NewMoo since March 2024. Prior to this role, Michal held the positions of CTO and VP R&D at NeoTX Therapeutics LTD, leading all research and development activities focused on immuno-oncology products from September 2015 to March 2024. Previous experience includes serving as VP R&D at Efranat Ltd., overseeing anticancer research involving macrophage activating factors, and managing project timelines and budgets at TransPharma Medical as Director of Project Management. Michal also directed R&D efforts at Power Paper, led pre-clinical lab operations at Zetiq Technologies, and acted as a senior scientist and project leader at Balm Pharmaceuticals, focusing on peptide pharmacology. Michal earned a PhD in Biochemistry from Bar-Ilan University and conducted postdoctoral research at the Weizmann Institute of Science.